We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product
Product News

Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product

Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product
Product News

Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "Rosetta Genomics Completes Prevalidation Phase for First Diagnostic Product"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Rosetta Genomics, Ltd. has announced that it has completed the prevalidation phase for its first diagnostic test. Using a single microRNA, the test is designed to differentiate squamous from non-squamous lung cancer with high sensitivity and specificity.

Rosetta Genomics diagnostic tests are currently undergoing validation testing at Columbia University Medical Center at its Clinical Laboratory Improvement Amendments (CLIA) certified laboratory.

The company expects three diagnostic tests to be launched in 2008 including a test for cancer of unknown primary, lung cancer vs. mesothelioma, and the squamous vs. non-squamous lung cancer test which has recently passed the prevalidation phase.

"The results we have seen so far for our microRNA-based diagnostic tests are very encouraging," Said Amir Avniel, President and CEO of Rosetta Genomics. "Results of the prevalidation phase showed the test differentiated squamous from non-squamous lung cancer using microRNA biomarkers identified by us, with both high sensitivity and specificity. We expect the test to be available for clinical use in the first half of 08."

Advertisement